Recently a study
was published in the Milbank Quarterly analyzing the voting patterns of FDA Advisory Committee members with apparent conflicts of interest.
A protein called Nrf2,continually moves in and out of the nuclei of human cells to sense the cell's health and vitality and when Nrf2 is exposed to threats to the cell's health, it oscillates faster and activates an increase in the cell's defense mechanism, including raising the levels of antioxidants.
Generic drugs and biosimilar drugs are conceptually equivalent, though a biosimilar drug is not a generic drug.
Generics drugs are equivalent copycats - exact copies of molecules that were developed at great cost by companies that are now outside the patent window. Biosimilars are instead copies of molecules of a protein nature involving biological processes and materials, like cell culture or the extraction of products using living organisms, which is why there is no product that is exactly the same as the other. Basically, that is why the name 'biosimilar' exists, because unlike generics they are not 'bioequivalent' to the drugs that have survived rigorous testing and approval.
Treatment with xenon gas reduces the extent of brain damage after a head injury reduces the extent of brain damage, according to a new study.
Head injury is the leading cause of death and disability in people under 45 in developed countries - due primarily to falls and road accidents. The primary injury caused by the initial mechanical force is followed by a secondary injury which develops in the hours and days afterwards. This secondary injury is largely responsible for patients' mental and physical disabilities, but there are currently no drug treatments that can be given after the accident to stop it from occurring.
A team of researchers have evaluated mepolizumab, a new antibody-based drug for certain patients with severe asthma, and found it can replace traditional, steroid-based treatments for a specific subset of patients, resulting in improved outcomes and reduced side effects.
Patients with severe asthma often require high doses of steroid-based treatments that can significantly impair their quality of life.
These high doses can cause debilitating side effects including mood swings, diabetes, bone loss, skin bruising, cataracts and hypertension.
Previous research at the Hamilton institutions has identified specific types of patient with severe asthma have an overabundance of a particular type of white blood cell (eosinophils) present in their sputum.
While use of well-established medicine has declined among rich, liberal elites in America's wealthiest, most educated states, untested and sometimes dangerous herbal dietary supplement sales in the United States rose to $6,000,000,000 - an increase of 7.9% over 2013.
As expected, sales in "natural" food stores were strongest, rising by 8.8%, but even regular food and drug stores had a 7.7% over 2012 sales, reflecting a growing distrust of science among the organic and alternative medicine communities.
Data from FIRST (MM-020/IFM 07-01), an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant, have been published.
The initial findings, including that the trial had met its primary endpoint of progression free survival, were reported during the plenary session at the 55th American Society of Hematology annual meeting in December 2013.
Selective Serotonin Reuptake Inhibitors (SSRIs), the most widely used drugs for the treatment of depression, have been reported to reduce bone formation and increase the risk of bone fracture. Since osseointegration is influenced by bone metabolism, a new study investigated the association between SSRIs and the risk of failures in osseointegrated implants.
Within the limits of the study, the findings indicate that treatment with SSRIs is associated with an increased failure risk of osseointegrated implants.
Wockhardt Limited announced that two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food&Drug Administration (FDA).
QIDP status is granted to drugs which act against pathogens which have a high degree of unmet need in their treatment and are identified by the Centers for Disease Control. QIDP status allows for fast track review of the drug application by U.S. FDA, paving way for an early launch. This is the first instance of an Indian Pharmaceutical company receiving a QIDP status.
Energy drinks can cause heart problems according to research presented yesterday at the European Society of Cardiology Congress 2014 today by Professor Milou-Daniel Drici from France.